Tamara van Donge

Chapter 6 104 Table 1: Patient demographic characteristics and dosing information. Data presented as median (range) or number (percentage). Small for gestational age was determined as the birth weight lower than the 10 th percentile of the respective gestational growth curves. Patient characteristics Median (range) or n (%) Age at start of treatment (days) 3.1 (1.23 – 15.56) Birth weight (g) 780 (540 – 1150) Gestational age (weeks) 25.86 (23.43 – 27.39) Closure of ductus after start of treatment (days) 3 (2 – 5) Closure of ductus 13 (56%) Sex, female 12 (52%) Small for gestational age 5 (21%) PNA age groups at start of treatment PNA ≤ 3 days 11 (48%) PNA > 3 days 12 (52%) Adverse events Feeding intolerance Necrotising enterocolitis Renal impairment 5 (22%) 2 (9%) 2 (9%) Table 2: Correlations and predictive performance between various sampling time points after start of ibuprofen treatment and the probability to reach target exposure (AUC 0-72h of 900 mg·h/L). ROC: receiver operating characteristics. Time point of (R/S)-ibuprofen concentration assessment (hours since the first ibuprofen dose) Logistic regression with AUC 0-72h Correlation Coefficient (R 2 ) AUC-ROC for predicting AUC 0-72h > 900 mg·h/L 3 h 0.47 0.56 4 h 0.53 0.63 5 h 0.59 0.68 6 h 0.64 0.74 8 h 0.73 0.84 9 h 0.77 0.88 10 h 0.80 0.91 12 h 0.86 0.96 14 h 0.90 0.98 16 h 0.94 0.99 18 h 0.96 0.99 23.5 h (Cmin) 0.99 0.99